ViroLogic Announces Three-Year Service Agreement With GSK

ViroLogic has signed a three-year, $7.5 million service agreement with GlaxoSmithKline (GSK) to use ViroLogic's novel HIV resistance testing technology to support GSK's drug discovery and development programs. GSK plans to use ViroLogic's assays across its virology portfolio, including its entry inhibitor program, where ViroLogic's PhenoSense HIV Co-receptor Tropism assay will be used to identify patients for clinical trials and to monitor response to drug treatment during the trials. Entry inhibitors are a promising new treatment option for HIV-infected individuals.

BioSpace (http://www.biospace.com/news_story.cfm?StoryID=18911420&full=1)